Moving to diabetic nephropathy, a randomized, double-blind, placebo-controlled, multicenter, pilot study tested the effects of 32 mg/day RBX for 1 year in patients with T2 diabetes and persistent albuminuria [albumin-to-creatinine ratio (ACR) 200–2,000 mg/g], despite renin-angiotensin system (RAS) inhibitors (154). Here, ALB is linked to diabetic kidney disease.